MK-0159 is an orally active, potent and selective CD38 inhibitor (h/m/r CD38 IC50 = 22/3/70 nM) that increases extra- and intracellular NAD+ levels in high CD38-expressing human epithelial A549 cultures, as well as intracellular NAD+/NADP+ in HMVECs (0.3-50 µM). MK-0159 (3-30 mg/kg p.o.) increases systemic NAD+ and decreases ADPR levels in mice, providing protection from myocardial damage upon cardiac I/R injury in vivo (30 mg/kg p.o.).
Potent and selective CD38 inhibitor that protects mice from myocardial damage upon cardiac I/R injury in vivo.
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Faites votre choix parmi les versions les plus récentes :
Infection is one of the major causes of mortality in patients with systemic lupus erythematosus (SLE). We previously found that CD38, an ectoenzyme that regulates the production of NAD+, is up-regulated in CD8+ T cells of SLE patients and correlates
Journal of medicinal chemistry, 65(13), 9418-9446 (2022-06-29)
CD38 is one of the major nicotinamide adenine dinucleotide (NAD+)- and nicotinamide adenine dinucleotide phosphate (NADP+)-consuming enzymes in mammals. NAD+, NADP+, and their reduced counterparts are essential coenzymes for numerous enzymatic reactions, including the maintenance of cellular and mitochondrial redox
Questions
Reviews
★★★★★ No rating value
Active Filters
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
